Compile Data Set for Download or QSAR
maximum 50k data
Found 10 of ic50 for monomerid = 124183
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared...More data for this Ligand-Target Pair
In DepthDetails US Patent